Topadur Pharma AG, a Swiss biopharmaceutical company developing innovative therapies for aging-related diseases, announces the appointment of Professor Thierry Carrel, MD, to its Board of Directors. Professor Carrel is one of Switzerland’s most accomplished cardiac surgeons. His expertise in clinical needs, regulatory navigation, and innovative technologies will provide strategic direction as To

Topline results for RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, expected in 4Q2025 Enrollment continues in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline results expected in 2H2026 Startup activities for CREAATE, a pivotal Phase 3 study of deucrictibant for the prophylactic and on-demand treatment of AA

Funding combines equity investment and convertible loan. Focus on best-in-class, clinical-stage peanut allergen-neutralizing antibody MY006. Further potential for developing Mabylon’s discovery and pre-clinical pipeline programs. These include MY010, a multi-specific and cross-reactive antibody targeting the birch Bet v 1 allergen, as well as all the major birch-related tree, fruit and nuts alle

Novochizol, Aquagri and its partner companies today announced the launch of AgrINovo, a transformative collaborative project. AgrINovo aims to unlock the full potential of Novochizol technology to foster a healthier, more sustainable agriculture in India and worldwide.